K-Bio & Drug Development
Expanding global market share for Korean bio CDMOs and rapid growth in the GLP-1 obesity treatment market. Key investment opportunities in Samsung Biologics and Celltrion's biosimilar/CDMO competitiveness and global pharma's GLP-1 innovation.
Investment Confidence
Theme Analysis
Key Drivers
- Global CDMO market growing 10%+ annually
- GLP-1 obesity treatment market projected at $100B
- Korean biosimilar global market share expansion
- Next-gen bio technologies including ADC, cell/gene therapy
Risk Factors
- Clinical trial failure risk
- Drug pricing regulation tightening (U.S. IRA)
- CDMO competition intensifying (China/India)
- FX and raw material volatility
Catalysts
- Samsung Biologics Plant 5 commencing operations
- Eli Lilly/Novo Nordisk GLP-1 indication expansion
- Celltrion new biosimilar FDA approval
- ADC pipeline clinical results announcement
Sub-Themes(4)
Bio CDMO
The biopharmaceutical CDMO (Contract Development and Manufacturing Organization) market is growing 10%+ annually. Samsung Biologics, Lonza, and WuXi Biologics are competing for global capacity, while complex production processes for next-gen biologics like ADCs and bispecific antibodies are structurally expanding CDMO demand.
GLP-1 & Obesity Treatments
The GLP-1 obesity treatment market opened by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) is rapidly growing toward a $100B+ TAM by 2030. Innovation continues with oral GLP-1 and next-gen triple agonists, with Korean pharma pipelines (Hanmi Pharma) also drawing attention.
Biosimilars
The global biosimilar market is growing 15%+ annually as blockbuster drug patents expire. Celltrion and Samsung Bioepis are the two Korean pillars competing to launch biosimilars for Humira, Keytruda, and Eylea. The U.S. IRA drug pricing negotiation law is accelerating biosimilar adoption.
ADC & Antibody-Drug Conjugates
ADCs (Antibody-Drug Conjugates) linking antibodies with cytotoxic drugs have emerged as the core of next-gen cancer treatment. Daiichi Sankyo's Enhertu pioneered the market, and big pharma (Merck, AbbVie, Gilead) are investing trillions in acquiring ADC pipelines. Alteogen's subcutaneous injection platform (ALT-B4) is gaining attention as an ADC delivery innovation.
Related Investment Ideas
5Samsung Biologics — Global #1 CDMO Capacity, Growth Accelerating with Plant 5
Global #1 in biopharmaceutical contract manufacturing (CDMO) capacity. Plant 5 (180kL) brings total capacity to 780kL. Growing orders driven by global big pharma new drug pipeline expansion and high utilization rates.
Eli Lilly — Undisputed Leader in the GLP-1 Obesity Treatment Market
Leading the GLP-1 obesity treatment market with Mounjaro/Zepbound. Obesity drug revenue alone forecast at $30B+ in 2026. Mid-to-long-term growth secured through pipeline diversification including oral GLP-1 and Alzheimer's treatments.
Celltrion — Global Biotech Leap with Biosimilars + Proprietary Drugs
Korea's #1 biosimilar company. Following global success with Remsima (infliximab) and Truxima (rituximab), developing a Keytruda (pembrolizumab) biosimilar. Margin improvement through Celltrion Healthcare merger and proprietary distribution. Pursuing de-risking from biosimilar dependence with proprietary drug pipeline.
Hanmi Pharmaceutical — GLP-1 Efpeglenatide, Hope for K-Bio New Drugs
Proprietary GLP-1 receptor agonist efpeglenatide demonstrates differentiated efficacy and once-weekly dosing convenience in diabetes/obesity trials. Global expansion materializing through technology licensing agreements in China, Europe. Multiple bio new drug pipeline based on LAPS (Long-Acting Protein/Peptide Discovery) platform.
Alteogen — Subcutaneous Injection Platform ALT-B4, Core of ADC Administration Innovation
Hyaluronidase-based subcutaneous (SC) injection platform ALT-B4 converts IV to SC administration. Multiple technology licensing agreements with global big pharma including Merck (MSD), Roche, and BMS. ADC SC conversion dramatically improves patient convenience and hospital efficiency, driving explosive demand. Big pharma technology licensing milestones and royalties form a long-term cash cow.